BLOG > Publications & Citations > Discovery of a selective ERAP1 inhibitor for Hedgehog-dependent cancer treatment

Authors: Bufalieri, Francesca et al.
Source: Molecular Therapy, Volume 34, Issue 1, 582 - 605
We're delighted to share insights from a recent study entitled "Discovery of a new selective ERAP1 inhibitor for Hedgehog-dependent cancer treatment" published in Molecular Therapy by Bufalieri, Francesca et al:
Congratulations to all the authors on this excellent article!
They identified Canthin-6-one (N1) as a selective inhibitor of ERAP1 that effectively suppresses the Hedgehog (HH) signaling pathway. Their research demonstrates that this inhibitor significantly impairs tumor growth and reduces the self-renewal capability of stem-like cells in medulloblastoma and basal cell carcinoma models.
DreamFect Gold was used for the efficient transfection of MEF cells with various luciferase reporters and plasmids, supporting the investigation of molecular mechanisms and pathway activity in this study.
Read the article See DreamFect Gold
